National Academy of Agricultural Sciences (NAAS)
 |
PRINT ISSN : 2319-7692 Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The evolution of multidrug-resistant (MDR) Klebsiella pneumoniae constitutes a foremost public health issue, owing to the relatively limited antibiotic arsenal. Thereby, this research was undertaken to explore the in vitro susceptibility of MDR K. pneumoniae isolates from Mansoura University Hospital (MUH), Egypt to tigecycline and colistin. Over a 12-month study period, a total of 120 K. pneumoniae isolates were recovered. The MDR K. pneumoniae isolates accounted for 49.2% (59 out of 120). Amongst these isolates, 91.5% (54/59) were susceptible to tigecycline by Etest (MICs range; 0.25-1 μg/ml, MIC50; 0.5 μg/ml, and MIC90; 1 μg/ml), whereas 89.8% (53/59) were colistin-susceptible (MICs range; 0.5-2 μg/ml, MIC50; 1 μg/ml, and MIC90; 2 μg/ml). Extended-spectrum β-lactamase (ESBL) production was verified in 71.2% of the MDR strains, of which 95.2% and 92.9% were susceptible to tigecycline and colistin, respectively. In addition, 87.5% and 81.25% of the carbapenemase-positive-MDR K. pneumoniae strains displayed sensitivity to tigecycline and colistin, respectively. In conclusion, tigecycline and colistin exhibited striking in vitro activity against MDR K. pneumoniae isolates, including ESBL- and carbapenemase-producers. However, judicious use of these antibiotics is mandatory to avert the forthcoming threat of resistance to promising antibiotic classes.
 |
 |
 |
 |
 |
